Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-6400 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| ALN-6400 (Treatment Group A) | EXPERIMENTAL | Participants will be administered multiple doses of ALN-6400. |
| ALN-6400 (Treatment Group B) | EXPERIMENTAL | Participants will be administered multiple doses of ALN-6400. |
| Part A: ALN-6400 | EXPERIMENTAL | Participants will be administered a single dose of ALN-6400. |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo. |
| Part B: ALN-6400 | EXPERIMENTAL | Participants will be administered multiple doses of ALN-6400. |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants will be administered multiple doses of placebo. |
| Name | Type | Description |
|---|---|---|
| ALN-6400 | DRUG | ALN-6400 will be administered subcutaneously (SC). |
| Placebo | DRUG | Placebo will be administered subcutaneously (SC) |
Inclusion Criteria - * Is an adolescent or adult patient with a diagnosis of VWD (including Type 1, Type 2, Type 3, and platelet-type VWD) and HMB for 2 cycles during screening Exclusion Criteria - * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2 times the u...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Vonicog Alfa, ADVATE |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE2 | ALN-6400 |
| Hemab Therapeutics Holdings, Inc. | COAG | 2 | PHASE1 | HMB-002 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | - | Undisclosed |
ALN-6400 is an investigational drug being studied for the treatment of Von Willebrand Disease (VWD) and Hereditary Hemorrhagic Telangiectasia (HHT). It is also being evaluated in patients with heavy menstrual bleeding associated with VWD. The drug is currently in clinical development and has not been approved by regulatory authorities.
ALN-6400 targets plasminogen, a protein involved in the breakdown of blood clots. By targeting plasminogen, the drug may help reduce bleeding episodes in conditions like Von Willebrand Disease and Hereditary Hemorrhagic Telangiectasia. The drug is being developed as a small molecule therapy.
ALN-6400 is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company. Alnylam is conducting clinical trials to evaluate the safety and efficacy of ALN-6400 in patients with bleeding disorders. The company is listed on the stock exchange under the ticker symbol ALNY.
ALN-6400 is in Phase 1 and Phase 2 clinical development. A Phase 1 study is evaluating the drug in healthy volunteers and patients with Hereditary Hemorrhagic Telangiectasia. A Phase 2 study is recruiting female patients with Von Willebrand Disease and heavy menstrual bleeding. The drug is investigational and not yet approved.
ALN-6400 is being studied in two clinical trials. NCT06659640 is a Phase 1 study in healthy volunteers and patients with Hereditary Hemorrhagic Telangiectasia, conducted in the United States, Australia, Canada, France, Germany, and Spain. NCT07575308 is a Phase 2 study in female patients with Von Willebrand Disease and heavy menstrual bleeding, conducted in the United States.
ALN-6400 is a distinct investigational drug being developed by Alnylam Pharmaceuticals. It is not known to be the same as any other marketed medication. The drug is being studied under its own name in clinical trials for bleeding disorders.